Pharsight

Axumin is owned by Blue Earth.

Axumin contains Fluciclovine F-18.

Axumin has a total of 7 drug patents out of which 0 drug patents have expired.

Axumin was authorised for market use on 27 May, 2016.

Axumin is available in solution;intravenous dosage forms.

Axumin can be used as method of diagnosing tumors using positron emission tomography, positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment.

The generics of Axumin are possible to be released after 30 December, 2035.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10953112	BLUE EARTH	Precursor compound of radioactive halogen-labeled organic compound	Nov, 2026 (3 years from now)
US9387266	BLUE EARTH	Precursor compound of radioactive halogen-labeled organic compound	Nov, 2026 (3 years from now)
US10010632	BLUE EARTH	Precursor compound of radioactive halogen-labeled organic compound	Nov, 2026 (3 years from now)
US10933147	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (12 years from now)
US10967077	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (12 years from now)
US10716868	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (12 years from now)
US10124079	BLUE EARTH	Imaging of metastatic or recurrent cancer	Dec, 2035 (12 years from now)

Drugs and Companies using FLUCICLOVINE F-18 ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Method of diagnosing tumors using positron emission tomography; Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment

Dosage: SOLUTION;INTRAVENOUS